Abeona Therapeutics (NASDAQ:ABEO) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $18.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. HC Wainwright reissued a buy rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Wednesday, August 14th. StockNews.com raised Abeona Therapeutics from a sell rating to a hold rating in a research note on Tuesday, September 10th. Finally, Stifel Nicolaus started coverage on Abeona Therapeutics in a research note on Thursday, May 30th. They set a buy rating and a $21.00 target price on the stock.

Abeona Therapeutics Stock Down 2.7 %

Shares of NASDAQ:ABEO opened at $5.86 on Friday. The business has a 50-day moving average price of $5.24 and a 200 day moving average price of $5.40. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a current ratio of 7.48, a quick ratio of 7.48 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $240.04 million, a price-to-earnings ratio of -1.83 and a beta of 1.53.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.42). Sell-side analysts expect that Abeona Therapeutics will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ABEO. Acadian Asset Management LLC acquired a new position in shares of Abeona Therapeutics in the first quarter worth $91,000. Jump Financial LLC purchased a new position in Abeona Therapeutics in the fourth quarter valued at $199,000. Bank of New York Mellon Corp grew its stake in Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Abeona Therapeutics during the 2nd quarter worth about $1,732,000. Finally, Renaissance Technologies LLC raised its position in Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.